1. Home
  2. |Insights
  3. |PODCAST: Foreign Investment and Reviews by CFIUS Under the New Administration — C&M's First 100 Days Series

PODCAST: Foreign Investment and Reviews by CFIUS Under the New Administration — C&M's First 100 Days Series

Client Alert | 1 min read | 03.16.17

Alan Gourley and Addie Cliffe, both partners in Crowell & Moring’s International Trade and Government Contracts groups, sit down to provide a high-level overview of CFIUS and what it means for trade. Alan counsels clients with respect to a broad range of international and government contract issues. He has extensive experience with all aspects of international contracts, both government and commercial. Addie advises clients across a spectrum of government contracts and international trade compliance issues, with specialties including U.S. export controls, the Buy American Act, the Trade Agreements Act, and other U.S. laws and regulations applicable to international transactions.

Covered in this 13 minute podcast

  • Overview of CFIUS.
  • Current trends surrounding CFIUS.
  • Practical tips for businesses regarding M&A activity and foreign investment.
  • What can be gleaned from the annual CFIUS report to Congress.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights